BICO Group (BICO.ST) Stock Analysis & AI Equity Report

Medical - Devices SEK Explore free reports

BICO Group (BICO.ST) overview

BICO Group (BICO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, BICO Group reported revenue of SEK 1,946m and operating profit of SEK -289m; the year-end share price was 32.02 SEK and market capitalisation was SEK 2,260m. BICO Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BICO Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 2,985mFY 2024
Share price32.02 SEKFY 2024 year end
RevenueSEK 1,946mFY 2024
Operating profitSEK -289mFY 2024
Net earningsSEK -7.7mFY 2024
Market capitalisationSEK 2,260mFY 2024 year end

Figures updated on 2026-07-18. Data will be refreshed during report generation.

About BICO Group

BICO Group AB provides life science research tools and automation for laboratories. Its portfolio includes lab automation software, automated workstations, imaging systems, 3D bioprinters, bioprinting materials, single-cell dispensing, liquid handling, and mixing technologies. The company serves pharmaceutical, biotech, and academic customers seeking to streamline workflows, improve reproducibility, and support research in cell biology and drug development.

Generate the BICO Group report

BICO Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for BICO Group and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.